The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Midatech Pharma American Shares Risk To Be Delisted Amid Low Bid Price

Tue, 17th Dec 2019 16:39

(Alliance News) - Midatech Pharma PLC on Monday said it has secured a notification from NASDAQ Stock Market LLC stating that Midatech share price is not in compliance with the minimum bid requirement for continued listing on NASDAQ Capital Market in New York.

Midatech explained that one of the NASDAQ listing rules requires the company's shares to maintain a minimum bid price of USD1.00 per share. A failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

Based on the Midatech's American depositary share price of USD0.58 as of Tuesday, it no longer meets the minimum bid price requirement. Each ADS represents 20 Midatech shares. In London, Midatech shares closed up 4.4% at 2.40 pence each on Tuesday.

Looking ahead, the AIM-listed biotechnology firm said it has a grace period of 180 days, or until June 8 next year, to regain compliance with the minimum bid price requirement, meaning that Midatech shares should meet or exceed USD1.00 per share for at least ten consecutive business days during the compliance period.

If the shares do not regain compliance with the minimum bid price requirement during the compliance period, Midatech said it may be eligible for an additional grace period of 180 calendar day.

If it does not regain compliance during the initial grace period and is not eligible for an additional grace period, its shares will be delisted from NASDAQ Capital Market.

In that event, Midatech said it may appeal such determination to a hearing panel.

"The company intends to monitor the bid price of its depositary shares during the compliance period and will consider taking such actions as may be necessary and appropriate to achieve compliance with continued listing requirements prior to the expiration of all available grace periods," Midatech said in its statement Tuesday.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
24 Feb 2020 16:02

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
8 Jan 2020 15:51

Midatech shares surge on success of latest MTD201 study

(Sharecast News) - Biotechnology research and development company Midatech Pharma announced positive headline results from 'study 102' on Wednesday, which it said met its primary endpoints to confirm similar pharmacokinetics and bioavailability of octreotide for subcutaneous and intramuscular routes of administration.

Read more
8 Jan 2020 09:51

Positive Headline Reading For Latest Midatech MTD201 Study

Positive Headline Reading For Latest Midatech MTD201 Study

Read more
5 Dec 2019 15:59

Midatech Pharma Gets EU Grant For Brain Cancer Drug

Midatech Pharma Gets EU Grant For Brain Cancer Drug

Read more
4 Nov 2019 18:47

Armistice Capital Takes Almost 10% Interest In Midatech Pharma

Armistice Capital Takes Almost 10% Interest In Midatech Pharma

Read more
24 Oct 2019 11:50

Midatech Pharma Childhood Cancer Drug Given FDA Orphan Designation

Midatech Pharma Childhood Cancer Drug Given FDA Orphan Designation

Read more
23 Oct 2019 09:29

Midatech Pharma Inks USD3.0 Million Registered Direct Offering Deal

Midatech Pharma Inks USD3.0 Million Registered Direct Offering Deal

Read more
8 Oct 2019 11:34

Midatech Doses First Patients In MTD201 Administration Method Study

Midatech Doses First Patients In MTD201 Administration Method Study

Read more
8 Oct 2019 09:24

Midatech Pharma doses first volunteers in acromegaly treatment study

(Sharecast News) - Midatech Pharma on Tuesday announced that its MTD201 Phase 1 study for the treatment of acromegaly and neuroendocrine tumours has commenced.

Read more
7 Oct 2019 15:45

DIRECTOR DEALINGS: Midatech Pharma CFO Buys GBP30,000 In Shares

DIRECTOR DEALINGS: Midatech Pharma CFO Buys GBP30,000 In Shares

Read more
3 Oct 2019 15:40

DIRECTOR DEALINGS: Midatech Pharma CFO Stephen Stamp Buys Shares

DIRECTOR DEALINGS: Midatech Pharma CFO Stephen Stamp Buys Shares

Read more
30 Sep 2019 19:06

Midatech Pharma Slims Interim Loss As Cancer Treatments Progress

Midatech Pharma Slims Interim Loss As Cancer Treatments Progress

Read more
24 Sep 2019 14:32

Midatech Pharma Applies To US Regulator For Share Issue Authority

Midatech Pharma Applies To US Regulator For Share Issue Authority

Read more
20 Sep 2019 15:43

Midatech Pharma gets approval for next MTD201 study

(Sharecast News) - Biotechnology company Midatech Pharma has received approval to commence a phase 1 study on MTD201, which it is developing for the treatment of acromegaly and neuroendocrine tumours (NET).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.